<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01990768</url>
  </required_header>
  <id_info>
    <org_study_id>47114</org_study_id>
    <secondary_id>5U01HL077863-09</secondary_id>
    <secondary_id>TATRC Log No. 13335004-A</secondary_id>
    <nct_id>NCT01990768</nct_id>
  </id_info>
  <brief_title>Prehospital Tranexamic Acid Use for Traumatic Brain Injury</brief_title>
  <acronym>TXA</acronym>
  <official_title>Prehospital Tranexamic Acid Use for Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Defence Research and Development Canada</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary aim: To determine the efficacy of two dosing regimens of TXA initiated in the
      prehospital setting in patients with moderate to severe TBI (GCS score ≤12).

      Primary hypothesis: The null hypothesis is that random assignment to prehospital
      administration of TXA in patients with moderate to severe TBI will not change the proportion
      of patients with a favorable long-term neurologic outcome compared to random assignment to
      placebo, based on the GOS-E at 6 months.

      Secondary aims: To determine differences between TXA and placebo in the following outcomes
      for patients with moderate to severe TBI treated in the prehospital setting with 2 dosing
      regimens of TXA:

        -  Clinical outcomes: ICH progression, Marshall and Rotterdam CT classification scores, DRS
           at discharge and 6 months, GOS-E at discharge, 28-day survival, frequency of
           neurosurgical interventions, and ventilator-free, ICU-free, and hospital-free days.

        -  Safety outcomes: Development of seizures, cerebral ischemic events, myocardial
           infarction, deep venous thrombosis, and pulmonary thromboembolism.

        -  Mechanistic outcomes: Alterations in fibrinolysis based on fibrinolytic pathway
           mediators and degree of clot lysis based on TEG.

      Inclusion: Blunt and penetrating traumatic mechanism consistent with TBI with prehospital GCS
      ≤ 12 prior to administration of sedative and/or paralytic agents, prehospital SBP ≥ 90 mmHg,
      prehospital intravenous (IV) access, age ≥ 15yrs (or weight ≥ 50kg if age is unknown), EMS
      transport destination based on standard local practices determined to be a participating
      trauma center.

      Exclusion: Prehospital GCS=3 with no reactive pupil, estimated time from injury to start of
      study drug bolus dose &gt;2 hours, unknown time of injury, clinical suspicion by EMS of seizure
      activity, acute MI or stroke or known history, to the extent possible, of seizures,
      thromboembolic disorders or renal dialysis, CPR by EMS prior to randomization, burns &gt; 20%
      TBSA, suspected or known prisoners, suspected or known pregnancy, prehospital TXA or other
      pro-coagulant drug given prior to randomization, subjects who have activated the &quot;opt-out&quot;
      process when required by the local regulatory board.

      A multi-center double-blind randomized controlled trial with 3 treatment arms:

        -  Bolus/maintenance: 1 gram IV TXA bolus in the prehospital setting followed by a 1 gram
           IV maintenance infusion initiated on hospital arrival and infused over 8 hours.

        -  Bolus only: 2 grams IV TXA bolus in the prehospital setting followed by a placebo
           maintenance infusion initiated on hospital arrival and infused over 8 hours.

        -  Placebo: Placebo IV bolus in the prehospital setting followed by a placebo maintenance
           infusion initiated on hospital arrival and infused over 8 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Overview This multi-center, Phase II trial is designed to determine if Tranexamic Acid
           (TXA) initiated in the prehospital setting improves long-term neurologic outcome
           compared to placebo in patients with moderate to severe TBI who are not in shock. This
           study protocol will be conducted as part of the Resuscitation Outcomes Consortium (ROC)
           at trauma centers in the United States and Canada. ROC is funded by the National Heart
           Lung and Blood Institute (NHLBI) in partnership with the US Army Medical Research and
           Materiel Command (USAMRMC), Canadian Institutes of Health Research, the Heart &amp; Stroke
           Foundation of Canada, the American Heart Association (AHA), and the Defense Research and
           Development Canada. ROC is a clinical trials network focusing on research primarily in
           the area of prehospital cardiopulmonary arrest and severe traumatic injury. The mission
           of ROC is to provide infrastructure and project support for clinical trials and other
           outcome-oriented research in the areas of cardiopulmonary arrest and severe traumatic
           injury that lead to evidence-based change in clinical practice.

        2. Specific Aims/Hypothesis Statement

           2.1 Clinical Hypotheses and Aims

           Specific aim 1: To compare 6-month neurologic outcome between subjects who are randomly
           assigned to TXA to subjects who are randomly assigned to placebo by evaluating the
           Glasgow Outcome Scale Extended score (GOS-E) at 6 months post-injury.

           Primary Hypotheses: We will perform a one-sided test of the following null hypothesis:
           The proportion of subjects who have a favorable neurologic outcome (GOS-E &gt; 4) at six
           months post injury who are randomly assigned to TXA is not different from the proportion
           of subjects who have a favorable neurologic outcome (GOS-E &gt; 4) who are randomly
           assigned to placebo. This hypothesis will be tested versus the alternative that the
           proportion of subjects with a favorable neurologic outcome who are randomly assigned to
           TXA is higher than in subjects who are randomly assigned to placebo at the .1 level and
           versus the alternative that the proportion of subjects with a favorable neurologic
           outcome who are randomly assigned to TXA is lower than it is in the placebo group at the
           .025 level

           Specific aim 2: To assess differences in morbidity and mortality measured from
           randomization through 28 days or initial hospital discharge and differences in
           neurologic outcomes at 6 months between subjects in the bolus/maintenance arm, bolus
           only arm, and placebo arm.

           Secondary Hypotheses: The null hypotheses are that there will be no difference between
           subjects who are randomly assigned to TXA and subjects who are randomly assigned to
           placebo in the following: both absolute and relative volume of intracranial hemorrhage
           (ICH) progression, proportion of subjects with ICH progression, frequency of
           neurosurgical interventions, GOS-E measured at discharge and 6 months, Disability Rating
           Scale score (DRS) measured at discharge and 6 months, 28-day survival, and
           ventilator-free, intensive care unit (ICU)-free, and hospital-free days.

           Specific aim 3: To assess differences in adverse events measured from randomization to
           initial hospital discharge between subjects in the bolus/maintenance arm, bolus only
           arm, and placebo arm.

           Tertiary Hypotheses: The null hypotheses are that there will be no difference between
           subjects who are randomly assigned to TXA and subjects who are randomly assigned to
           placebo in the following: proportion of subjects experiencing seizures, cerebral
           ischemic events, myocardial infarction (MI), deep venous thrombosis (DVT), or pulmonary
           thromboembolism (PE) post randomization through 28 days or discharge, whichever occurs
           first.

           2.2 Laboratory Hypotheses and Aims

           Specific aim 1: To compare coagulation profiles over time using kaolin activated
           thrombelastography (TEG) results between subjects who are randomly assigned to TXA and
           subjects who are randomly assigned to placebo.

           Primary hypothesis: The null hypothesis is that there will be no difference in the
           degree of fibrinolysis as assessed by percentage of clot lysis determined 30 minutes
           after the maximum amplitude is reached (LY30) between subjects who are randomly assigned
           to TXA and subjects who are randomly assigned to placebo.

           Specific aim 2: To explore the underlying mechanism of TXA by comparing fibrinolytic
           pathway mediator activity between subjects who are randomly assigned to TXA and subjects
           who are randomly assigned to placebo.

           Secondary hypothesis: The null hypothesis is that there will be no change in
           fibrinolytic pathway mediators between subjects who are randomly assigned to TXA and
           subjects who are randomly assigned to placebo.

           Specific aim 3: To estimate the association between the degree of fibrinolysis based on
           kaolin activated TEG results and fibrinolytic pathway mediators on primary and secondary
           clinical outcomes.

           Tertiary hypothesis: The null hypothesis is that no association will exist between the
           degree of fibrinolysis and fibrinolytic pathway mediators and primary and secondary
           clinical outcomes.

        3. Study Enrollment

           EMS agencies will carry blinded sealed study drug kits. Once the seal is broken in the
           presence of the patient, the patient is randomized. The EMS study drug kit will contain
           a vial of either 1 gram TXA, 2 grams TXA, or placebo. EMS will mix the study drug in a
           250 mL bag of 0.9% sodium chloride and administer the bolus infusion as soon as
           life-saving interventions are performed. After randomization, EMS will provide the study
           drug kit ID# to the receiving pharmacy. The hospital pharmacist will obtain the
           randomization assignment from the coordinating center and prepare the appropriate drug
           to be administered in the hospital.

        4. Sample Size and Statistical Analysis

           The total sample size is 963 (321 per group) starting treatment, which will allow for
           80% power to detect a 7.1% absolute difference in favorable long-term neurological
           outcome as determined by the GOS-E 6 months after injury comparing the combined TXA
           treatment groups to placebo, using a one-sided, level 0.1 test.

           Statistical analysis of primary hypothesis: Modified intention-to-treat analysis using
           logistic regression to test for association and estimate the strength of the association
           of treatment group with a favorable 6-month outcome (defined as a GOS-E &gt; 4), after
           adjustment for study site.

        5. Human subjects protection

      This study qualifies for the exception from informed consent (EFIC) required for emergency
      research outlined in FDA regulation 21CFR50.24. EFIC applies because of life-threatening
      situation, intervention must be administered before consent is feasible, no reasonable way to
      identify prospectively individuals at risk, patients have the prospect of benefit from the
      treatment, and the research could not practically be carried out without the waiver of
      consent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">November 7, 2017</completion_date>
  <primary_completion_date type="Actual">November 7, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dichotomized Glasgow Outcome Scale Extended (GOS-E) at 6 Months</measure>
    <time_frame>6 months post-injury</time_frame>
    <description>GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died Within 28 Days</measure>
    <time_frame>28 days after hospital arrival</time_frame>
    <description>The counts of patients who died on or before day 28 are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability Rating Scale (DRS) at 6 Months</measure>
    <time_frame>6 months post-injury</time_frame>
    <description>The DRS is designed to classify patients based on their degree of function after brain injury. The DRS consists of 8 items that fall into 4 categories: (a) arousability, awareness and responsivity, (b) cognitive ability for self-care activities, (c) dependence on others, and (d) psychosocial adaptability. The score ranges from 0 (no disability) to 30 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unfavorable Outcome on Dichotomized Glasgow Outcome Scale Extended (GOS-E) at Discharge</measure>
    <time_frame>At the end of the hospital stay (average of 9 days post injury)</time_frame>
    <description>GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes. The number of subjects with unfavorable outcome is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability Rating Scale (DRS) at Discharge</measure>
    <time_frame>At the end of the hospital stay (average of 9 days post injury)</time_frame>
    <description>The DRS is designed to classify patients based on their degree of function after brain injury. The DRS consists of 8 items that fall into 4 categories: (a) arousability, awareness and responsivity, (b) cognitive ability for self-care activities, (c) dependence on others, and (d) psychosocial adaptability. The score ranges from 0 (no disability) to 30 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Intracranial Hemorrhage (ICH) Progression</measure>
    <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 13 days among patients with multiple scans)</time_frame>
    <description>All clinically indicated head computed tomography (CT) scans obtained during the initial hospitalization or within the first 28 days were assessed for ICH. Parenchymal (IPH), subdural (SDH) and epidural (EDH) hemorrhage volumes were measured and quantified using volumetric software and verified by manual calculations based on the previously validated ABC/2 technique. The sum of the IPH, SDH, and EDH volumes were compared across scans. A relative increase of 33% (and at least a 1 ml increase) on any subsequent scan compared to the initial scan was defined as a progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marshall Computed Tomography (CT) Score on Initial Head CT</measure>
    <time_frame>Initial head CT (average of 1.9 hours post-injury)</time_frame>
    <description>The Marshall classification categorizes patients into one of six categories (I to VI) of increasing severity on the basis of findings on non-contrast CT scan of the brain. Higher categories have worse prognosis and survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rotterdam Computed Tomography (CT) Score Among Subjects With Intracranial Hemorrhage (ICH) on Initial Head CT</measure>
    <time_frame>Initial head CT (average of 1.9 hours post-injury)</time_frame>
    <description>The Rotterdam classification includes four independently scored elements: degree of basal cistern compression, degree of midline shift, presence of epidural hematomas, and presence of intraventricular or subarachnoid blood. The elements are combined to form an overall score from 1 to 6 with higher scores having worse prognosis and survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Neurosurgical Interventions</measure>
    <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
    <description>Neurosurgical interventions include craniotomy, craniectomy, and placement of a neuromonitoring or drainage device. Counts are of subjects with one or more neurosurgical interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free Days</measure>
    <time_frame>From hospital admission through day 28</time_frame>
    <description>Hospital-free days count any day from hospital admission through day 28 that the patient is alive and out of the hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit (ICU)-Free Days</measure>
    <time_frame>From hospital admission through day 28</time_frame>
    <description>ICU-free days count any day from hospital admission through day 28 that the patient is alive and not in the ICU. Subjects who die prior to discharge (even if after 28 days) are assigned a value of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free Days</measure>
    <time_frame>From hospital admission through day 28</time_frame>
    <description>Ventilator-free days count any day from hospital admission through day 28 that the patient is alive and does not require mechanical ventilatory support. Subjects who die prior to discharge (even if after 28 days) are assigned a value of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seizure</measure>
    <time_frame>From start of study drug infusion through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
    <description>Seizures may cause involuntary changes in body movement or function, sensation, awareness, or behavior. Seizures are often associated with a sudden and involuntary contraction of a group of muscles and loss of consciousness. Seizures or episodes of seizure-like activity were reported by medics in the field following the start of study drug infusion through hand-off to the trauma center and by trauma center staff through discharge. Reported events were included if providers gave anti-seizure medication and/or the event was confirmed by EEG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cerebral Ischemic Event</measure>
    <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
    <description>Diagnosis of cerebral ischemic event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
    <description>Diagnosis of an acute myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deep Vein Thrombosis (DVT)</measure>
    <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
    <description>Diagnosis of DVT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pulmonary Embolus (PE)</measure>
    <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
    <description>Diagnosis of PE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Thromboembolic Event</measure>
    <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
    <description>Diagnosis of one or more of the following: cerebral ischemic event, myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE), or any other thromboembolic event</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fibrinolysis at Hospital Admission</measure>
    <time_frame>First blood draw (average of 1.6 hours post-injury)</time_frame>
    <description>Alterations in fibrinolysis based on fibrinolytic pathway mediators and degree of clot lysis based on kaolin-activated thromboelastography (TEG) and defined as LY30 or the per cent lysis that occurs 30 minutes after maximum amplitude (MA) is achieved. LY30 is categorized as &lt;0.8% (fibrinolysis shutdown), 0.8-3% (normal), and &gt;3% (hyperfibrinolysis).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">967</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>1 gram Tranexamic Acid (TXA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose of 1 gram TXA given prior to hospital arrival followed by a 1 gram TXA infusion over 8 hours after hospital arrival</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 grams TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose of 2 gram TXA given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% Sodium Chloride injectable</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 gram Tranexamic Acid (TXA)</intervention_name>
    <description>TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.</description>
    <arm_group_label>1 gram Tranexamic Acid (TXA)</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 grams TXA</intervention_name>
    <description>TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.</description>
    <arm_group_label>2 grams TXA</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Sodium Chloride injectable</intervention_name>
    <description>Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.</description>
    <arm_group_label>0.9% Sodium Chloride injectable</arm_group_label>
    <other_name>Normal saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Blunt or penetrating traumatic mechanism consistent with traumatic brain injury

          2. Prehospital Glasgow Coma Score (GCS) score ≤ 12 at any time prior to randomization and
             administration of sedative and/or paralytic agents

          3. Prehospital systolic blood pressure (SBP) ≥ 90 mmHg prior to randomization

          4. Prehospital intravenous (IV) or intraosseous (IO) access

          5. Estimated Age ≥ 15 (or estimated weight &gt; 50 kg if age is unknown)

          6. Emergency Medicine System (EMS) transport to a participating trauma center

        Exclusion Criteria:

          1. Prehospital GCS=3 with no reactive pupil

          2. Estimated time from injury to hospital arrival &gt; 2 hours

          3. Unknown time of injury - no known reference times to support estimation

          4. Clinical suspicion by EMS of seizure activity or known history of seizures, acute
             myocardial infarction (MI) or stroke

          5. Cardio-pulmonary resuscitation (CPR) by EMS prior to randomization

          6. Burns &gt; 20% total body surface area (TBSA)

          7. Suspected or known prisoners

          8. Suspected or known pregnancy

          9. Prehospital TXA given prior to randomization

         10. Subjects who have activated the &quot;opt-out&quot; process when required by the local
             regulatory board
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne May, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Schreiber, MD FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Resuscitation Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Paul Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Center for Resuscitation Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milwaukee Resuscitation Research Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Regional Coordinating Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1 M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto RescuNet</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>November 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <results_first_submitted>November 7, 2018</results_first_submitted>
  <results_first_submitted_qc>December 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2019</results_first_posted>
  <last_update_submitted>December 31, 2018</last_update_submitted>
  <last_update_submitted_qc>December 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Susanne May</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>traumatic brain injury</keyword>
  <keyword>intracranial hemorrhage</keyword>
  <keyword>prehospital</keyword>
  <keyword>neurologic outcome</keyword>
  <keyword>glasgow outcome scale extended</keyword>
  <keyword>disability rating scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Public use data set will be shared with NHLBI. It will include individual patient data that are de-identified. It will be available 3 years after study completion. This is currently expected for the end of 2020. The data should then be available at &lt;https://biolincc.nhlbi.nih.gov/studies/&gt;.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form: Protocol in force at beginning of enrollment</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 3, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01990768/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form: Protocol after Amendment 2</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01990768/Prot_SAP_ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form: Protocol after Amendment 2.1</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01990768/Prot_SAP_ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between May 2015 and March 2017, participants were enrolled by 39 emergency management service (EMS) agencies and transported to 20 trauma centers within 12 regional sites in North America.</recruitment_details>
      <pre_assignment_details>Some persons for whom the blinded study kit was opened did not actually receive any of the study drug. These persons are not included in the enrollment numbers. However, they are enumerated in the first section of the patient flow tables.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
        </group>
        <group group_id="P2">
          <title>Bolus-Maintenance</title>
          <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
        </group>
        <group group_id="P3">
          <title>Bolus Only</title>
          <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention Started</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="345"/>
                <participants group_id="P3" count="373"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Found to be ineligible</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study drug issue or kit malfunction</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient became ineligible due to vitals</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not enough time for EMS to enroll</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient care priority</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>IV lost</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required CPR</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Seizure or hx of seizure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discovered to be pregnant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Prehospital Study Drug Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="285"/>
                <participants group_id="P3" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Seizure or concern for seizure</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required CPR</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other safety concern</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discharged</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Emergency unblinding</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown if completed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>In-Hospital Study Drug Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="229"/>
                <participants group_id="P3" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discharged</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death or comfort care</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Emergency unblinding</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Seizure or concern for seizure</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>CVA/thrombotic event or concern for one</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required CPR</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other safety concern</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Taken into police custody</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Found not to be injured</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transfer to non-participating facility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other procoagulant administered</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown if completed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>6-Month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="261"/>
                <participants group_id="P3" count="288"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Calls unreturned or refused contact</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No contact information</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Homeless</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prisoner at time of enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prisoner at time of follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient at psychiatric hospital</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
        </group>
        <group group_id="B2">
          <title>Bolus-Maintenance</title>
          <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
        </group>
        <group group_id="B3">
          <title>Bolus Only</title>
          <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="309"/>
            <count group_id="B2" value="312"/>
            <count group_id="B3" value="345"/>
            <count group_id="B4" value="966"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="309"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="345"/>
                    <count group_id="B4" value="966"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="25" upper_limit="55"/>
                    <measurement group_id="B2" value="39" lower_limit="26" upper_limit="57"/>
                    <measurement group_id="B3" value="40" lower_limit="26" upper_limit="56"/>
                    <measurement group_id="B4" value="38" lower_limit="25" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="309"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="345"/>
                    <count group_id="B4" value="966"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="251"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="255"/>
                    <measurement group_id="B4" value="715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Ethnicity was not reported at Canadian sites.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="309"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="345"/>
                    <count group_id="B4" value="966"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="251"/>
                    <measurement group_id="B4" value="700"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Race was not reported at Canadian sites.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="309"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="345"/>
                    <count group_id="B4" value="966"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="227"/>
                    <measurement group_id="B4" value="642"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="309"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="345"/>
                    <count group_id="B4" value="966"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="309"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="345"/>
                    <count group_id="B4" value="966"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="309"/>
                    <measurement group_id="B4" value="878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Penetrating injury</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="309"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="345"/>
                    <count group_id="B4" value="966"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cause of injury</title>
          <population>Cause of injury missing on 1 placebo participant and 5 bolus only participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="308"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="340"/>
                    <count group_id="B4" value="960"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Motor vehicle occupant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="331"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Motor vehicle motorcycle</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Motor vehicle bicycle/pedestrian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fall at ground level</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fall at more than 1 meter</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Assault</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Suicide</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prehospital Glasgow Coma Scale</title>
          <description>Neurological scale used to assess the level of consciousness following traumatic brain injury. Scores range from 3 to 15. Scores of 3-8 are generally considered severe, 9-12 moderate, and 13-15 minor.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="309"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="345"/>
                    <count group_id="B4" value="966"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>3-8</title>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="177"/>
                    <measurement group_id="B4" value="532"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9-12</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="403"/>
                  </measurement_list>
                </category>
                <category>
                  <title>13-15</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injury Severity Score (ISS)</title>
          <description>The Injury Severity Score is a measure used to assess trauma severity. It is correlated with mortality, morbidity, and hospital length of stay. The score ranges between 0 (no injury) and 75 (unsurvivable injury). Scores greater than 15 are defined as major trauma.</description>
          <population>ISS is sometimes not available if the patient dies early or there is insufficient information about injuries in specific body regions. The measure is missing for 7 placebo, 8 bolus-maintenance, and 3 bolus only participants.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="304"/>
                    <count group_id="B3" value="342"/>
                    <count group_id="B4" value="948"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" lower_limit="9" upper_limit="27"/>
                    <measurement group_id="B2" value="17" lower_limit="8" upper_limit="27"/>
                    <measurement group_id="B3" value="17" lower_limit="8" upper_limit="27"/>
                    <measurement group_id="B4" value="17" lower_limit="9" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Head Abbreviated Injury Score (AIS)</title>
          <description>The Abbreviated Injury Scale is an anatomical-based coding system used to classify and describe the severity of injuries. The scores for a particular region range from 0 (no injury) to 6 (unsurvivable injury).</description>
          <population>Head AIS is sometimes not available if the patient dies early or there is insufficient information about injuries to the head. The measure is missing for 8 placebo, 6 bolus-maintenance, and 1 bolus only participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="301"/>
                    <count group_id="B2" value="306"/>
                    <count group_id="B3" value="344"/>
                    <count group_id="B4" value="951"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0-1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="265"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5-6</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dichotomized Glasgow Outcome Scale Extended (GOS-E) at 6 Months</title>
        <description>GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes.</description>
        <time_frame>6 months post-injury</time_frame>
        <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O4">
            <title>Combined TXA Arms</title>
            <description>Includes both the Bolus-Maintenance (1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours) and Bolus Only (2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours) treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Dichotomized Glasgow Outcome Scale Extended (GOS-E) at 6 Months</title>
          <description>GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes.</description>
          <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="345"/>
                <count group_id="O4" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Unfavorable GOS-E (&lt;=4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Favorable GOS-E (&gt;4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="178"/>
                    <measurement group_id="O4" value="331"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing GOS-E</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This study was designed with an asymmetric boundary for tests for treatment harm and benefit. The conventional 0.025 level was used to test for harm while a 0.1 level was used to determine benefit for this Phase II trial. Statistical significance for the primary analysis was conducted under a group-sequential design that included a single, interim futility analysis using a Wang-Tsiatis boundary with parameter 0.8 based on outcome data from the first 200 subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.1809</p_value>
            <p_value_desc>Based on an interim futility analysis, a one-sided P-value less than .1028 was required to declare benefit.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Analysis was adjusted for regional site. Missing outcomes were multiply imputed.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.87</param_value>
            <ci_n_sides>1-Sided</ci_n_sides>
            <estimate_desc>Odds ratio for unfavorable GOS-E (&lt;=4) for the Combined TXA Arms (numerator) vs. Placebo (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died Within 28 Days</title>
        <description>The counts of patients who died on or before day 28 are reported.</description>
        <time_frame>28 days after hospital arrival</time_frame>
        <population>Subjects for whom study drug administration was started and 28-day vital status was definitively obtained. Patients excluded from the counts include subjects who withdrew from the study prior to day 28 and subjects who were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died Within 28 Days</title>
          <description>The counts of patients who died on or before day 28 are reported.</description>
          <population>Subjects for whom study drug administration was started and 28-day vital status was definitively obtained. Patients excluded from the counts include subjects who withdrew from the study prior to day 28 and subjects who were lost to follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="285"/>
                <count group_id="O3" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disability Rating Scale (DRS) at 6 Months</title>
        <description>The DRS is designed to classify patients based on their degree of function after brain injury. The DRS consists of 8 items that fall into 4 categories: (a) arousability, awareness and responsivity, (b) cognitive ability for self-care activities, (c) dependence on others, and (d) psychosocial adaptability. The score ranges from 0 (no disability) to 30 (death).</description>
        <time_frame>6 months post-injury</time_frame>
        <population>Subjects for whom study drug administration was started and DRS questions were obtained at 6 months. Excluded subjects include those who withdrew prior to 6 months after injury and those lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Disability Rating Scale (DRS) at 6 Months</title>
          <description>The DRS is designed to classify patients based on their degree of function after brain injury. The DRS consists of 8 items that fall into 4 categories: (a) arousability, awareness and responsivity, (b) cognitive ability for self-care activities, (c) dependence on others, and (d) psychosocial adaptability. The score ranges from 0 (no disability) to 30 (death).</description>
          <population>Subjects for whom study drug administration was started and DRS questions were obtained at 6 months. Excluded subjects include those who withdrew prior to 6 months after injury and those lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="11.8"/>
                    <measurement group_id="O2" value="8.1" spread="11.9"/>
                    <measurement group_id="O3" value="6.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unfavorable Outcome on Dichotomized Glasgow Outcome Scale Extended (GOS-E) at Discharge</title>
        <description>GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes. The number of subjects with unfavorable outcome is reported.</description>
        <time_frame>At the end of the hospital stay (average of 9 days post injury)</time_frame>
        <population>Subjects for whom study drug administration was started and for whom Glasgow Outcome Score Extended was obtained at discharge. Subjects who withdrew prior to discharge make up most of the subjects who were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unfavorable Outcome on Dichotomized Glasgow Outcome Scale Extended (GOS-E) at Discharge</title>
          <description>GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes. The number of subjects with unfavorable outcome is reported.</description>
          <population>Subjects for whom study drug administration was started and for whom Glasgow Outcome Score Extended was obtained at discharge. Subjects who withdrew prior to discharge make up most of the subjects who were excluded from this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="294"/>
                <count group_id="O3" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disability Rating Scale (DRS) at Discharge</title>
        <description>The DRS is designed to classify patients based on their degree of function after brain injury. The DRS consists of 8 items that fall into 4 categories: (a) arousability, awareness and responsivity, (b) cognitive ability for self-care activities, (c) dependence on others, and (d) psychosocial adaptability. The score ranges from 0 (no disability) to 30 (death).</description>
        <time_frame>At the end of the hospital stay (average of 9 days post injury)</time_frame>
        <population>Subjects for whom study drug administration was started and for whom discharge Disability Rating Scale was obtained. Subjects who withdrew prior to discharge make up most of the subjects who were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Disability Rating Scale (DRS) at Discharge</title>
          <description>The DRS is designed to classify patients based on their degree of function after brain injury. The DRS consists of 8 items that fall into 4 categories: (a) arousability, awareness and responsivity, (b) cognitive ability for self-care activities, (c) dependence on others, and (d) psychosocial adaptability. The score ranges from 0 (no disability) to 30 (death).</description>
          <population>Subjects for whom study drug administration was started and for whom discharge Disability Rating Scale was obtained. Subjects who withdrew prior to discharge make up most of the subjects who were excluded from this analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="294"/>
                <count group_id="O3" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="11.1"/>
                    <measurement group_id="O2" value="9.4" spread="11.0"/>
                    <measurement group_id="O3" value="8.1" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Intracranial Hemorrhage (ICH) Progression</title>
        <description>All clinically indicated head computed tomography (CT) scans obtained during the initial hospitalization or within the first 28 days were assessed for ICH. Parenchymal (IPH), subdural (SDH) and epidural (EDH) hemorrhage volumes were measured and quantified using volumetric software and verified by manual calculations based on the previously validated ABC/2 technique. The sum of the IPH, SDH, and EDH volumes were compared across scans. A relative increase of 33% (and at least a 1 ml increase) on any subsequent scan compared to the initial scan was defined as a progression.</description>
        <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 13 days among patients with multiple scans)</time_frame>
        <population>Subjects for whom study drug administration was started and for whom two or more analyzable head CT scans were obtained prior to a hematoma evacuation. Excluded subjects primarily include those who died or withdrew before an initial or second CT scan was taken, who had a hematoma evacuation prior to a second scan, or who had only one negative CT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Intracranial Hemorrhage (ICH) Progression</title>
          <description>All clinically indicated head computed tomography (CT) scans obtained during the initial hospitalization or within the first 28 days were assessed for ICH. Parenchymal (IPH), subdural (SDH) and epidural (EDH) hemorrhage volumes were measured and quantified using volumetric software and verified by manual calculations based on the previously validated ABC/2 technique. The sum of the IPH, SDH, and EDH volumes were compared across scans. A relative increase of 33% (and at least a 1 ml increase) on any subsequent scan compared to the initial scan was defined as a progression.</description>
          <population>Subjects for whom study drug administration was started and for whom two or more analyzable head CT scans were obtained prior to a hematoma evacuation. Excluded subjects primarily include those who died or withdrew before an initial or second CT scan was taken, who had a hematoma evacuation prior to a second scan, or who had only one negative CT.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Marshall Computed Tomography (CT) Score on Initial Head CT</title>
        <description>The Marshall classification categorizes patients into one of six categories (I to VI) of increasing severity on the basis of findings on non-contrast CT scan of the brain. Higher categories have worse prognosis and survival.</description>
        <time_frame>Initial head CT (average of 1.9 hours post-injury)</time_frame>
        <population>Subjects who received an initial head computed tomography scan with sufficient information to be scored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Marshall Computed Tomography (CT) Score on Initial Head CT</title>
          <description>The Marshall classification categorizes patients into one of six categories (I to VI) of increasing severity on the basis of findings on non-contrast CT scan of the brain. Higher categories have worse prognosis and survival.</description>
          <population>Subjects who received an initial head computed tomography scan with sufficient information to be scored.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="290"/>
                <count group_id="O3" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Diffuse injury I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Diffuse injury II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Diffuse injury III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Diffuse injury IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mass lesion V/VI</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rotterdam Computed Tomography (CT) Score Among Subjects With Intracranial Hemorrhage (ICH) on Initial Head CT</title>
        <description>The Rotterdam classification includes four independently scored elements: degree of basal cistern compression, degree of midline shift, presence of epidural hematomas, and presence of intraventricular or subarachnoid blood. The elements are combined to form an overall score from 1 to 6 with higher scores having worse prognosis and survival.</description>
        <time_frame>Initial head CT (average of 1.9 hours post-injury)</time_frame>
        <population>Subjects determined by the central image reviewer to have an intracranial hemorrhage (ICH) on the initial head computed tomography (CT) scan and sufficient information to assign the Rotterdam score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Rotterdam Computed Tomography (CT) Score Among Subjects With Intracranial Hemorrhage (ICH) on Initial Head CT</title>
          <description>The Rotterdam classification includes four independently scored elements: degree of basal cistern compression, degree of midline shift, presence of epidural hematomas, and presence of intraventricular or subarachnoid blood. The elements are combined to form an overall score from 1 to 6 with higher scores having worse prognosis and survival.</description>
          <population>Subjects determined by the central image reviewer to have an intracranial hemorrhage (ICH) on the initial head computed tomography (CT) scan and sufficient information to assign the Rotterdam score.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With One or More Neurosurgical Interventions</title>
        <description>Neurosurgical interventions include craniotomy, craniectomy, and placement of a neuromonitoring or drainage device. Counts are of subjects with one or more neurosurgical interventions.</description>
        <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
        <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Neurosurgical Interventions</title>
          <description>Neurosurgical interventions include craniotomy, craniectomy, and placement of a neuromonitoring or drainage device. Counts are of subjects with one or more neurosurgical interventions.</description>
          <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital-free Days</title>
        <description>Hospital-free days count any day from hospital admission through day 28 that the patient is alive and out of the hospital.</description>
        <time_frame>From hospital admission through day 28</time_frame>
        <population>Subjects for whom study drug administration was started and for whom discharge status was known. Subjects who withdrew prior to discharge make up most of the subjects who were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital-free Days</title>
          <description>Hospital-free days count any day from hospital admission through day 28 that the patient is alive and out of the hospital.</description>
          <population>Subjects for whom study drug administration was started and for whom discharge status was known. Subjects who withdrew prior to discharge make up most of the subjects who were excluded from this analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="292"/>
                <count group_id="O3" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="10.7"/>
                    <measurement group_id="O2" value="13.6" spread="10.7"/>
                    <measurement group_id="O3" value="14.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit (ICU)-Free Days</title>
        <description>ICU-free days count any day from hospital admission through day 28 that the patient is alive and not in the ICU. Subjects who die prior to discharge (even if after 28 days) are assigned a value of 0.</description>
        <time_frame>From hospital admission through day 28</time_frame>
        <population>Subjects for whom study drug administration was started and for whom number of ICU days through 28 days was known. Subjects who withdrew prior to discharge make up most of the subjects who were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit (ICU)-Free Days</title>
          <description>ICU-free days count any day from hospital admission through day 28 that the patient is alive and not in the ICU. Subjects who die prior to discharge (even if after 28 days) are assigned a value of 0.</description>
          <population>Subjects for whom study drug administration was started and for whom number of ICU days through 28 days was known. Subjects who withdrew prior to discharge make up most of the subjects who were excluded from this analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="10.6"/>
                    <measurement group_id="O2" value="18.1" spread="10.8"/>
                    <measurement group_id="O3" value="19.1" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator-free Days</title>
        <description>Ventilator-free days count any day from hospital admission through day 28 that the patient is alive and does not require mechanical ventilatory support. Subjects who die prior to discharge (even if after 28 days) are assigned a value of 0.</description>
        <time_frame>From hospital admission through day 28</time_frame>
        <population>Subjects for whom study drug administration was started and for whom number of ventilator days through 28 days was known. Subjects who withdrew prior to discharge make up most of the subjects who were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator-free Days</title>
          <description>Ventilator-free days count any day from hospital admission through day 28 that the patient is alive and does not require mechanical ventilatory support. Subjects who die prior to discharge (even if after 28 days) are assigned a value of 0.</description>
          <population>Subjects for whom study drug administration was started and for whom number of ventilator days through 28 days was known. Subjects who withdrew prior to discharge make up most of the subjects who were excluded from this analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="10.5"/>
                    <measurement group_id="O2" value="19.9" spread="10.8"/>
                    <measurement group_id="O3" value="20.9" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seizure</title>
        <description>Seizures may cause involuntary changes in body movement or function, sensation, awareness, or behavior. Seizures are often associated with a sudden and involuntary contraction of a group of muscles and loss of consciousness. Seizures or episodes of seizure-like activity were reported by medics in the field following the start of study drug infusion through hand-off to the trauma center and by trauma center staff through discharge. Reported events were included if providers gave anti-seizure medication and/or the event was confirmed by EEG.</description>
        <time_frame>From start of study drug infusion through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
        <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seizure</title>
          <description>Seizures may cause involuntary changes in body movement or function, sensation, awareness, or behavior. Seizures are often associated with a sudden and involuntary contraction of a group of muscles and loss of consciousness. Seizures or episodes of seizure-like activity were reported by medics in the field following the start of study drug infusion through hand-off to the trauma center and by trauma center staff through discharge. Reported events were included if providers gave anti-seizure medication and/or the event was confirmed by EEG.</description>
          <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cerebral Ischemic Event</title>
        <description>Diagnosis of cerebral ischemic event</description>
        <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
        <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cerebral Ischemic Event</title>
          <description>Diagnosis of cerebral ischemic event</description>
          <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Diagnosis of an acute myocardial infarction</description>
        <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
        <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Diagnosis of an acute myocardial infarction</description>
          <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deep Vein Thrombosis (DVT)</title>
        <description>Diagnosis of DVT</description>
        <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
        <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deep Vein Thrombosis (DVT)</title>
          <description>Diagnosis of DVT</description>
          <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pulmonary Embolus (PE)</title>
        <description>Diagnosis of PE</description>
        <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
        <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pulmonary Embolus (PE)</title>
          <description>Diagnosis of PE</description>
          <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Thromboembolic Event</title>
        <description>Diagnosis of one or more of the following: cerebral ischemic event, myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE), or any other thromboembolic event</description>
        <time_frame>From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)</time_frame>
        <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Thromboembolic Event</title>
          <description>Diagnosis of one or more of the following: cerebral ischemic event, myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE), or any other thromboembolic event</description>
          <population>Subjects for whom study drug administration was started minus one Bolus Only arm subject who was mistakenly enrolled while in police custody.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fibrinolysis at Hospital Admission</title>
        <description>Alterations in fibrinolysis based on fibrinolytic pathway mediators and degree of clot lysis based on kaolin-activated thromboelastography (TEG) and defined as LY30 or the per cent lysis that occurs 30 minutes after maximum amplitude (MA) is achieved. LY30 is categorized as &lt;0.8% (fibrinolysis shutdown), 0.8-3% (normal), and &gt;3% (hyperfibrinolysis).</description>
        <time_frame>First blood draw (average of 1.6 hours post-injury)</time_frame>
        <population>Subjects with an LY30 measurement at hospital admission are included. Subjects who were transported to trauma centers without a TEG machine, who died prior to the initial blood draw, or who withdrew or refused a blood draw were excluded. Additional exclusions included blood draw missed by study staff and technical difficulties with processing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O2">
            <title>Bolus-Maintenance</title>
            <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
          <group group_id="O3">
            <title>Bolus Only</title>
            <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrinolysis at Hospital Admission</title>
          <description>Alterations in fibrinolysis based on fibrinolytic pathway mediators and degree of clot lysis based on kaolin-activated thromboelastography (TEG) and defined as LY30 or the per cent lysis that occurs 30 minutes after maximum amplitude (MA) is achieved. LY30 is categorized as &lt;0.8% (fibrinolysis shutdown), 0.8-3% (normal), and &gt;3% (hyperfibrinolysis).</description>
          <population>Subjects with an LY30 measurement at hospital admission are included. Subjects who were transported to trauma centers without a TEG machine, who died prior to the initial blood draw, or who withdrew or refused a blood draw were excluded. Additional exclusions included blood draw missed by study staff and technical difficulties with processing.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;0.8 (fibrinolysis shutdown)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>0.8-3% (normal)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;3% (hyperfibrinolysis)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were captured from the beginning of study drug infusion on day 0 through day 28. While follow-up time varies by patient due to withdrawals, transfers to non-participating hospitals, deaths, and participants lost to follow-up, all analysis patients were &quot;at risk&quot; for adverse events during at least some period of time and are thus included in all adverse event denominators.</time_frame>
      <desc>Chart reviews were made daily. Events prespecified as possibly related to study drug were categorized for seriousness by site PIs and are listed in both the &quot;Serious&quot; and &quot;Other&quot; AE sections below. Other events (marked with &quot;^&quot;) were monitored and reported but not considered adverse events of the study drug. These are listed in the &quot;Other&quot; AE section since they were not assessed for seriousness. One Bolus Only arm subject who was mistakenly enrolled while in police custody is excluded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo IV bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
        </group>
        <group group_id="E2">
          <title>Bolus-Maintenance</title>
          <description>1 gram IV TXA bolus in the prehospital setting followed by a 1 gram IV maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
        </group>
        <group group_id="E3">
          <title>Bolus Only</title>
          <description>2 grams IV TXA bolus in the prehospital setting followed by a placebo maintenance infusion initiated on hospital arrival and infused over 8 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction (MI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident - hemorrhagic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - thrombotic</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism (PE)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral vascular emboli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cerebral venus sinus thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Embolic infarcts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Inferior vena cava thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Internal jugular vein thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Left ventricular thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest (non-fatal)^</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="309"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cardiac failure^</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Myocardial infarction (MI)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pseudomembranous colitis^</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Compartment Syndrome^</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Central diabetes insipidus^</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cerebral vasospams^</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="309"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Extremity Compartment Syndrome^</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis^</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Liver failure^</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bloodstream infection^</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Empyema^</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Intra-abdominal abscess^</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Meningitis^</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia^</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="309"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="312"/>
                <counts group_id="E3" events="45" subjects_affected="45" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sepsis^</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="309"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="312"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urinary tract infection (UTI)^</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="309"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="312"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Wound infection^</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypernatremia^</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="309"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="312"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident - hemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident - thrombotic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="309"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury (AKI)^</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="309"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="312"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Renal failure^</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome (ARDS)^</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="309"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="312"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism (PE)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral venus sinus thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Deep vein throbosis (DVT)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="309"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Superficial venus thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Susanne May</name_or_title>
      <organization>University of Washington, Resuscitation Outcomes Consortium</organization>
      <phone>206-685-1302</phone>
      <email>rochelp@uwctc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

